Document is current
Any future updates will be listed below
-
Authors
Giuliani, Luigi
Pezzella, Pasquale
Mucci, Armida
Palumbo, Davide
Caporusso, Edoardo
Piegari, Giuseppe
Giordano, Giulia Maria
Blasio, Pietro
Mencacci, Claudio
Torriero, Sara
Galderisi, Silvana
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05130853 at ClinicalTrials.govDocuments that mention this clinical trial
Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study
https://doi.org/10.1186/s12991-024-00535-9
- License Information
-
More Information
Article History
Received: 18 September 2024
Accepted: 5 December 2024
First Online: 28 December 2024
Declarations
:
: The protocol has been approved by the Ethics Committee of the Università degli Studi della Campania “Luigi Vanvitelli”—A.O.U. “Luigi Vanvitelli”, A.O.R.N. “Ospedale dei Colli” and by the Ethics Committee of ASST Fatebenefratelli-Sacco of Milan.
: Not applicable.
: This study received funding from Otsuka Pharmaceutical Italy s.r.l. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. AM has been a consultant and/or advisor to or has received honoraria from Angelini, Gedeon. Richter Bulgaria, Janssen Pharmaceuticals, Lundbeck, Otsuka Pharmaceutical, Pfizer, Pierre Fabre, Rovi. Pharma and Boehringer Ingelheim. GG has been a consultant for Angelini. SG has been a consultant and/or advisor to or has received honoraria from Angelini, Boehringer Ingelheim, Gedeon Richter-Recordati, Janssen, Lundbeck, Otsuka, ROVI.
